Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors
Authors: Dimitri Arangalage, Julie Delyon, Mathilde Lermuzeaux, Kenneth Ekpe, Stéphane Ederhy, Cécile Pages, Céleste Lebbé
Journal: Annals of Internal Medicine (2017)

Letters7 November 2017Survival After Fulminant Myocarditis Induced by Immune-Checkpoint InhibitorsDimitri Arangalage, MD*, Julie Delyon, MD*, Mathilde Lermuzeaux, MD, Kenneth Ekpe, MD, Stéphane Ederhy, MD, Cécile Pages, MD, and Céleste Lebbé, MD, PhDDimitri Arangalage, MD*From Assistance Publique–Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Saint-Louis Hospital, and Saint-Antoine Hospital; Université Paris Diderot; Sorbonne Paris Cité; and Institut National de la Santé et de la Recherche Médicale, Paris, France., Julie Delyon, MD*From Assistance Publique–Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Saint-Louis Hospital, and Saint-Antoine Hospital; Université Paris Diderot; Sorbonne Paris Cité; and Institut National de la Santé et de la Recherche Médicale, Paris, France., Mathilde Lermuzeaux, MDFrom Assistance Publique–Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Saint-Louis Hospital, and Saint-Antoine Hospital; Université Paris Diderot; Sorbonne Paris Cité; and Institut National de la Santé et de la Recherche Médicale, Paris, France., Kenneth Ekpe, MDFrom Assistance Publique–Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Saint-Louis Hospital, and Saint-Antoine Hospital; Université Paris Diderot; Sorbonne Paris Cité; and Institut National de la Santé et de la Recherche Médicale, Paris, France., Stéphane Ederhy, MDFrom Assistance Publique–Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Saint-Louis Hospital, and Saint-Antoine Hospital; Université Paris Diderot; Sorbonne Paris Cité; and Institut National de la Santé et de la Recherche Médicale, Paris, France., Cécile Pages, MDFrom Assistance Publique–Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Saint-Louis Hospital, and Saint-Antoine Hospital; Université Paris Diderot; Sorbonne Paris Cité; and Institut National de la Santé et de la Recherche Médicale, Paris, France., and Céleste Lebbé, MD, PhDFrom Assistance Publique–Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Saint-Louis Hospital, and Saint-Antoine Hospital; Université Paris Diderot; Sorbonne Paris Cité; and Institut National de la Santé et de la Recherche Médicale, Paris, France.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0396 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Some patients with metastatic melanoma live longer when they are treated with combinations of immune-checkpoint inhibitors (1, 2). However, up to 55% of these patients experience high-grade, immune-related adverse events (3–5). In phase 3 trials of these drugs, immune-related adverse events involving the heart affected only 0.19% of patients; fulminant myocarditis was the most serious of these (5).Objective: To report what we believe to be the first patient to survive fulminant myocarditis induced by immune-checkpoint inhibitors.Case Report: We admitted a 35-year-old woman with unresectable stage IIIc melanoma of the neck who developed progressive dyspnea 15 days after ...References1. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558-68. [PMID: 27622997] doi:10.1016/S1470-2045(16)30366-7 CrossrefMedlineGoogle Scholar2. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34. [PMID: 26027431] doi:10.1056/NEJMoa1504030 CrossrefMedlineGoogle Scholar3. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-55. [PMID: 27806233] CrossrefMedlineGoogle Scholar4. Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 2017;19:21. [PMID: 28220466] doi:10.1007/s11886-017-0835-0 CrossrefMedlineGoogle Scholar5. Ederhy S, Voisin A-L, Champiat S. Myocarditis with immune checkpoint blockade [Letter]. N Engl J Med. 2017;376:290-1. [PMID: 28102662] doi:10.1056/NEJMc1615251 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Assistance Publique–Hôpitaux de Paris, Bichat-Claude Bernard Hospital, Saint-Louis Hospital, and Saint-Antoine Hospital; Université Paris Diderot; Sorbonne Paris Cité; and Institut National de la Santé et de la Recherche Médicale, Paris, France.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0396.* Drs. Arangalage and Delyon contributed equally to this work. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImmunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment ImplicationsCardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic ReviewMyocarditis Induced by Immunotherapy in Metastatic Melanoma—Review of Literature and Current GuidelinesDiretriz de Miocardites da Sociedade Brasileira de Cardiologia – 2022The Potential Cardiotoxicity of Immune Checkpoint InhibitorsCardiology (Heart)Case Analysis of Immune-Related Myocarditis Induced by PD-1 InhibitorsManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateCase Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib TreatmentImmune Checkpoint Inhibitor–Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of CasesCardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategiesFulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literatureTreatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case seriesImmune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported casesPathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitorsLife-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: a case reportKeeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recoveryImmune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsySuccessful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature ReviewCardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic ReviewAcute cardiac manifestations under immune checkpoint inhibitors—beware of the obvious: a case reportSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsImmune checkpoint inhibitor–associated myocarditis: manifestations and mechanismsImmune Checkpoint Inhibitor (ICI)-Associated MyocarditisImmune Checkpoint Inhibitor (ICI)-Related CardiotoxicityCardiomyopathies and Arrhythmias Induced by Cancer TherapiesAdverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmiaImmune Checkpoint Inhibitor-Induced Myasthenia GravisManagement of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approachCardiovascular effects of innovative therapies in lung cancerNeue onkologische Therapien und ihre kardiovaskulären RisikenImmune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and TreatmentCardivascular Toxicities of ImmunotherapyClinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint InhibitorsCardiotoxicity from immune checkpoint inhibitorsImmune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and ManagementImmune checkpoint inhibitor–mediated myocarditis and ventricular tachycardia stormImmune checkpoint inhibitor therapy and myocarditis: a systematic review of reported casesCardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the LiteratureImmune checkpoint inhibitor myocarditisManagement of immune-related adverse events resulting from immune checkpoint blockadeMyocardial Dysfunction Associated with Cancer TherapyCheckpoint InhibitorsCardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance studyFatal autoimmune myocarditis with anti–PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancerReporting of immune checkpoint inhibitor-associated myocarditisMyocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to ActionManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineIpilimumab/nivolumab 7 November 2017Volume 167, Issue 9Page: 683-684KeywordsAdverse eventsCorticosteroid therapyDrugsExtracorporeal membrane oxygenationHyperthyroidismLeft ventricular ejection fractionMagnetic resonance imagingMelanomaMyocarditisT cells ePublished: 5 September 2017 Issue Published: 7 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...